Hepatitis C virus (HCV) Treatment complications and liver malfunction in patients suffering from hereditary beta thalassemia major is a concern. By introduction of direct-acting antivirals (DAAs) dramatically changing the landscape of hepatitis C. The aim of the present study was to evaluate treatment outcome of DAA therapy in thalassemia major patients infected with HCV in a three-year follow-up.

Hepatitis C virus (HCV) Treatment complications and liver malfunction in patients suffering from hereditary beta thalassemia major is a concern. By introduction of direct-acting antivirals (DAAs) dramatically changing the landscape of hepatitis C. The aim of the present study was to evaluate treatment outcome of DAA therapy in thalassemia major patients infected with HCV in a three-year follow-up.

From among 84 patients enrolled in the study, 53.6% were males, 36.9% had cirrhosis, 96.4% had a history of Desferal usage, and 78.6% had a history of splenectomy. Unfortunately, 7 participants (8.3%) died prior to the end of follow-up with nearly half of them having Iron overload and heart failure complications. Fibroscan score, ALT, AST, and ferritin were significantly lower compared with baseline evaluation, while Hb, creatinine, and direct bilirubin increased significantly in the third year after the treatment.

Safety and efficiency of Sofosbuvir and Daclatasvir in thalassemia patients assessed previously but our three-year follow-up showed their mild complications and death into a long-term period after DAAs treatment and 91.7% three-year survival rate, which may affected by other confounding factors, such as liver malfunction and Iron overload.